---
title: "Long-term complication profiles after transsphenoidal vs transcranial resection of adult craniopha"
id: "plos-one-9-long-term-complication-profiles-following-transsphenoidal-and-transcranial"
canonical_url: "https://medichelpline.com/clinical-feed/plos-one-9-long-term-complication-profiles-following-transsphenoidal-and-transcranial"
content_type: "clinical_feed_article"
specialty: "General"
source_name: "PLOS ONE (Medicine)"
source_url: "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0363328"
published_at: "2026-11-19T14:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Long-term complication profiles after transsphenoidal vs transcranial resection of adult craniopha
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/plos-one-9-long-term-complication-profiles-following-transsphenoidal-and-transcranial
- **Specialty:** [General](https://medichelpline.com/clinical-feed/general.md)
- **Primary Source:** PLOS ONE (Medicine)
- **Source URL:** [Original Journal Publication](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0363328)
- **Published At:** 2026-11-19T14:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- Investigators used the TriNetX US Collaborative Network to assemble a retrospective cohort of adult **craniopharyngioma** resections performed between 2005 and 2026. The dataset relied on ICD-10 and CPT coding and contained deidentified EHR data aggregated across participating centers. - The unadjusted cohort included 2,558 transsphenoidal resections (TSR) and 1,452 transcranial resections (TCR); preoperative features differed between groups, with more hydrocephalus and diabetes insipidus in TCR patients and more hypopituitarism among TSR patients. - Propensity score matching created 1,199 pairs balanced for demographics, comorbidities, presenting features, and prior radiation; Cox proportional hazards models estimated hazard ratios at 1, 5, 10, and 15 years. - At 1 year, TSR carried higher risk of cerebrospinal fluid leak but lower risks of mortality, hydrocephalus, blindness, and need for adjuvant radiation, as investigators reported. - At 10 years, TSR remained associated with lower hydrocephalus, diabetes insipidus (DI), and blindness but showed higher rates of hypopituitarism, higher composite endocrine morbidity, and persistent elevation in CSF leak risk. - Findings at intermediate (5-year) and long (15-year) time points were concordant with 1- and 10-year results, indicating durable divergence in complication profiles by approach. - The study used population-level, deidentified data; investigators noted that detailed individual-level clinical variables and certain granular operative data are not available through TriNetX and that access is restricted under data use agreements.
## Clinical Analysis & Structured Key Points
Long-term complication profiles following transsphenoidal and transcranial resection of adult craniopharyngioma: A retrospective cohort study | PLOS One Browse Subject Areas ? Click through the PLOS taxonomy to find articles in your field. For more information about PLOS Subject Areas, click here . Article Authors Metrics Comments Media Coverage Reader Comments Figures Figures Abstract Introduction Craniopharyngiomas arise in the sellar/suprasellar region and are managed with maximal safe resection via transsphenoidal (TSR) or transcranial (TCR) approaches. The optimal approach remains contested, as treatment must balance tumor control against long-term visual, endocrine, neurologic, and cerebrospinal fluid (CSF) leak–related morbidity. Longitudinal complication and morbidity profiles of craniopharyngioma resection in adults remain limited. We evaluated approach-specific long-term outcomes in a large multi-institutional adult cohort. Methods In a retrospective cohort study using the TriNetX network, adult craniopharyngioma patients undergoing TSR or TCR were compared using unmatched analyses and propensity score matching (PSM). Matching characteristics included demographics, comorbidities, presenting features, and prior radiation. Cox models estimated hazard ratios (HR) at 1, 5, 10, and 15 years from surgery. Results We identified 2,558 (41.0%) patients who underwent TSR and 1,452 (23.3%) who underwent TCR. Patients selected for TCR had more preoperative hydrocephalus and diabetes insipidus (DI), whereas TSR patients had more hypopituitarism. After PSM (1,199 pairs), TSR carried higher early CSF-leak risk (1-year HR:1.65, 95% confidence interval [CI]: 1.25–2.19, p < 0.001) but lower rates of 1-year mortality (HR:0.54, 95%CI:0.33–0.91, p = 0.02), hydrocephalus (HR:0.35, 95%CI:0.18–0.71, p = 0.002), blindness (HR:0.54, 95%CI:0.33–0.86, p = 0.009), and adjuvant radiation (HR:0.70, 95%CI:0.52–0.94, p = 0.02). At 10 years, TSR was associated with lower hydrocephalus (HR:0.57, 95%CI:0.35–0.93, p = 0.02), DI (HR:0.69, 95%CI:0.52–0.91, p = 0.01), and blindness (HR:0.61, 95%CI:0.43–0.86, p = 0.01), but higher hypopituitarism (HR:1.24, 95%CI:1.06–1.46, p = 0.01), higher composite endocrine morbidity (HR:1.23, 95%CI:1.03–1.46, p = 0.02), and persistently elevated CSF leak (HR:1.32, 95%CI:1.02–1.72, p = 0.04). Findings at 5 and 15 years were concordant. Conclusions Adults with craniopharyngioma experience substantial long-term visual, endocrine, hydrocephalus-related, and treatment-related morbidity. TSR and TCR were associated with distinct long-term complication profiles, with TSR generally associated with lower rates of hydrocephalus, blindness, epilepsy, and DI but higher rates of CSF leak and hypopituitarism. These findings provide long-term population-level estimates that may inform surgical counseling and postoperative surveillance. Citation: Zeng WL, Singla A, Cote DJ, Daggupati S, Dallas J, Briggs RG, et al. (2026) Long-term complication profiles following transsphenoidal and transcranial resection of adult craniopharyngioma: A retrospective cohort study. PLoS One 21(11): e0363328. https://doi.org/10.1371/journal.pone.0363328 Editor: Taiwo Opeyemi Aremu, Touro University California College of Pharmacy, UNITED STATES OF AMERICA Received: September 26, 2026; Accepted: November 6, 2026; Published: November 19, 2026 Copyright: © 2026 Zeng et al. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability: The data that supports the findings of this study are available from the TriNetX Research Network but restrictions apply to their availability. The data used in this study include deidentified individual participant data and associated data dictionaries; however, these data were accessed under license are not publicly available. Detailed cohort definitions, analytic methods, and all diagnostic and medication code lists used to generate the study cohorts are provided in the Supplementary section to facilitate reproducibility for researchers with access to the TriNetX Research Network. All data is available through TriNetX to researchers in accordance with TriNetX data use agreements and policies. Further information including contact information for data access can be found at https://trinetx.com . Funding: The author(s) received no specific funding for this work. Competing interests: The authors have declared that no competing interests exist. Introduction Craniopharyngiomas are rare epithelial tumors arising in the sellar and suprasellar region from remnants of Rathke’s pouch and account for approximately 2–5% of primary intracranial neoplasms [ 1 ]. Although histologically benign, these tumors are frequently associated with substantial morbidity because of their relationship with the optic nerves, hypothalamus, pituitary gland, third ventricle, and adjacent vascular structures [ 1 ]. Patients commonly present with visual dysfunction, endocrinopathy, hydrocephalus, headaches, or cognitive and behavioral disturbances [ 1 , 2 ]. Treatment often requires balancing durable tumor control against the risk of treatment-related neurologic and endocrine complications [ 2 , 3 ]. Surgical resection remains the cornerstone of management, typically performed using transcranial resection (TCR) or transsphenoidal resection (TSR), with radiation therapy frequently used for residual/recurrent disease [ 3 ]. Advances in endoscopic skull base surgery have expanded the role of transsphenoidal approaches for selected tumors, while transcranial approaches remain necessary for lesions with substantial lateral extension, vascular encasement, or complex third ventricular involvement [ 4 , 5 ]. However, evaluation of long-term postoperative complication profiles by surgical approach in adults remain limited. Historically, aggressive gross total resection (GTR) was pursued to maximize the long-term tumor control; however, increasing recognition of the profound morbidity associated with hypothalamic and pituitary injury has shifted management toward maximal safe resection with greater emphasis on functional preservation [ 6 ]. Contemporary studies have demonstrated that long-term sequelae following treatment may include diabetes insipidus (DI), hypopituitarism, obesity, visual decline, epilepsy, neurocognitive dysfunction, cerebrospinal fluid (CSF) leak, hydrocephalus, and reduced quality of life [ 7 , 8 ]. These complications may persist lifelong [ 2 , 9 ], underscoring the importance of understanding approach-specific long-term morbidity. Much of the existing literature on long-term outcomes after craniopharyngioma treatment has focused on pediatric populations, given the profound developmental and endocrine consequences of treatment during childhood, including hypothalamic obesity, neurocognitive impairment, impaired growth, and psychosocial dysfunction [ 10 , 11 ]. Several pediatric series have demonstrated that morbidity may persist decades after treatment, even among patients with durable tumor control [ 11 – 13 ]. In contrast, adult craniopharyngioma remains relatively understudied, with existing studies often limited by single-institution experiences, modest sample sizes, heterogeneous treatment paradigms, and short follow-up [ 9 , 14 , 15 ]. Many published adult cohorts focus primarily on tumor recurrence and progression-free survival rather than longitudinal complication profiles, and direct comparisons between TSR and TCR remain limited [ 5 , 9 , 16 – 18 ]. Thus, important gaps remain in understanding long-term neurologic, endocrinologic, and postoperative morbidity associated with different operative strategies in adults. Given these gaps in the literature, we performed a large multi-institutional retrospective cohort study using the US Collaborative Network within the TriNetX database to evaluate long-term outcomes following transsphenoidal and transcranial resection of adult craniopharyngioma. We assessed approach-specific complication profiles using propensity-matched analyses and unmatched real-world cohorts, with longitudinal follow-up extending 15 years after surgery. Our objective was to assess long-term associations between surgical approach and major neurologic, endocrinologic, and postoperative complications in a large adult population. Materials and methods Setting We performed a retrospective cohort study using the US Collaborative Network within the TriNetX Research Network (TriNetX, LLC), a federated database containing deidentified electronic health record data from participating healthcare institutions throughout the United States. TriNetX contains deidentified demographic, diagnostic, procedural, and medication data from participating U.S. healthcare institutions, with diagnoses and procedures coded using (International Classification of Diseases, Tenth Revision) ICD-10 and Current Procedural Terminology (CPT) systems. As the TriNetX platform provides only aggregated and deidentified population-level data, institutional review board and ethics committee approval were not sought or required for this study. Informed patient consent was not required or obtained. This study was conducted and reported in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines. Cohort Using CPT and ICD-10 codes, we identified adult patients (≥18 years) with a diagnosis of craniopharyngioma between January 1 st , 2005 and January 1 st , 2026 within the TriNetX Research Network. To evaluate the influence of treatment center type, patients were additionally stratified by whether the index resection was performed at an academic vs. non-academic center using the TriNetX healthcare-organization classification. Because historical craniopharyngioma diagnoses may persist into adulthood, we required a qualifying resection within 1 year of diagnosis to identify actively treated disease. Patients were then stratified into TCR and TSR cohorts based on procedural coding. To maximize cohort specificity, patients with transsphenoidal procedure codes were excluded from the TCR cohort, and those with transcranial procedure codes were excluded from the TSR cohort. A control cohort of patients with an outpatient encounter and no history of craniopharyngioma was constructed to contextualize systemic, neurologic, visual, endocrine, and metabolic morbidity. For comparative analyses between TCR and TSR cohorts, both unmatched and propensity score-matched (PSM) analyses were performed. Unmatched analyses were conducted to preserve the full study population and reflect real-world treatment selection patterns, while matched analyses were performed to reduce imbalance in baseline demographic clinical characteristics and partially mitigate the risk of selection bias between surgical cohorts. Complete coding definitions were determined a priori ( S1 File , Table A1). Statistics All analyses were conducted within the TriNetX platform, with the index date defined as the date of craniopharyngioma resection. Outcomes were evaluated at 1, 5, 10, and 15 years after index surgery. Propensity score matching was performed using age, sex, race, ethnicity (Hispanic or Latino vs. not Hispanic or Latino), body mass index (BMI), diabetes mellitus, hypertension, hyperlipidemia, chronic kidney disease, hydrocephalus, visual disturbances, hypopituitarism, DI, and prior radiation exposure. Greedy nearest-neighbor matching with a caliper of 0.1 pooled standard deviations was used, with standardized mean differences <0.1 indicating adequate balance. Outcomes of interest included neurologic, visual, endocrine, CSF-related, treatment-related, and metabolic complications, with composite visual, endocrine, and vascular outcomes ( S1 File , Table A1). For unmatched analyses, crude outcome incidence was calculated for each cohort. For matched analyses, outcomes were compared following propensity score matching to account for baseline differences in demographic and clinical characteristics. Time-to-event analyses were performed using Kaplan-Meier survival analysis with log-rank testing, and Cox proportional hazard models were used to calculate hazard ratios. Statistical significance was defined as p < 0.05. Results Cohort characteristics For the baseline risk analysis, 6,238 matched adult craniopharyngioma patients were compared with 6,238 matched ( S1 File , Table A2) healthy outpatient controls. For the surgical-approach analysis, only patients with a clearly defined operative approach were retained; those with an ambiguous approach or with codes indicating more than one resection type were excluded. Prior to PSM, the TSR and TCR cohorts comprised 2,558 (41.01%) and 1,452 (23.28%) patients, respectively ( Fig 1 ). Mean age at index surgery was similar between cohorts (51.7 ± 15.9 vs. 50.8 ± 14.7 years; SMD 0.059). With respect to baseline comorbidities, the TSR cohort demonstrated higher rates of essential hypertension (39.4% vs. 34.6%; SMD 0.100) and hypopituitarism (24.5% vs. 13.8%; SMD 0.275). In contrast, the TCR cohort demonstrated higher rates of DI (10.6% vs. 6.1%; SMD 0.165) and preoperative hydrocephalus (6.0% vs. 2.4%; SMD 0.178). After matching, 1,199 patients were included in each surgical cohort, and all covariates included in the propensity model were balanced (SMD < 0.1) ( Table 1 ). Download: PNG larger image TIFF original image Table 1. Baseline patient characteristics of TSR vs. TCR cohorts before and after propensity score matching. https://doi.org/10.1371/journal.pone.0363328.t001 Download: PNG larger image TIFF original image Fig 1. Study flow diagram of cohort identification, exclusions, and propensity score matching. https://doi.org/10.1371/journal.pone.0363328.g001 Visual flow diagram showing the detailed breakdown of patient cohorts. Each box represents a patient cohort, with the count remaining at that stage. Boxes branching to the side list excluded patients and the reason for exclusion. Connecting lines trace the progression from the source population to the final matched or unmatched cohorts. Long-term outcomes in adult craniopharyngioma patients versus healthy controls Compared with matched healthy controls, adult craniopharyngioma patients demonstrated substantially higher rates of visual, endocrine, hydrocephalus-related, and treatment-related morbidity at every interval from 1 to 15 years. At 10 years, these differences persisted, including composite visual complications (11.59% vs. 4.09%; HR:2.44, 95%CI:2.09–2.84, p < 0.001), hydrocephalus (2.08% vs. 0.64%; HR:2.82, 95%CI:1.99–4.01, p < 0.001), shunt placement (1.83% vs. 0.41%; HR:4.02, 95%CI:2.65–6.11, p < 0.001), hypopituitarism (27.76% vs. 0.62%; HR:44.72, 95%CI:31.66–63.16, p < 0.001), DI (10.68% vs. 0.51%; HR:20.06, 95%CI:14.04–28.66, p < 0.001), and composite endocrine complications (37.85% vs. 16.84%; HR:2.09, 95%CI:1.90–2.30, p < 0.001). Outcomes at 1, 5, and 15 years showed the same directional pattern ( S1 File , Tables A3–A6). Fig 2 summarizes baseline complication risk at 10 years. Download: PNG larger image TIFF original image Fig 2. Long-term complication risk in adult craniopharyngioma patients. https://doi.org/10.1371/journal.pone.0363328.g002 Forest plot of hazard ratios (HR) with 95% confidence intervals comparing adult craniopharyngioma patients to matched non-craniopharyngioma controls across postoperative and disease-related complications at 10-year follow-up. HRs greater than 1.0 indicate increased risk in the craniopharyngioma cohort relative to controls; HRs less than 1.0 indicate decreased risk. The dashed vertical reference line at HR = 1.0 denotes no difference between groups. Cohorts were propensity score-matched on age, sex, race/ethnicity, BMI, and comorbidities. Analysis includes adult patients (≥18 years) with a confirmed diagnosis of craniopharyngioma compared to a matched adult control population without craniopharyngioma. Outcomes without a plotted estimate had 10 or fewer patients with the outcome in at least one cohort; TriNetX reports counts of 1–10 as 10 to protect patient privacy and does not return effect estimates for these outcomes. Craniopharyngioma patients also had higher all-cause mortality than matched controls, concentrated in the early years after resection. Mortality was 4.16% vs. 1.90% at 1 year HR:2.14, 95%CI:1.73–2.64, p < 0.001), 7.72% vs. 5.51% at 5 years (HR:1.29, 95%CI:1.13–1.47, p < 0.001), and 10.99% vs. 7.72% at 10 years (HR:1.15, 95%CI:1.03–1.29, p = 0.02); by 15 years the hazard ratio was no longer significantly different, as the Kaplan–Meier curves converged in the second decade. Survival curves are shown in Fig 3A . Download: PNG larger image TIFF original image Fig 3. Kaplan-Meier survival for all-cause mortality in adult craniopharyngioma by diagnosis and surgical approach. https://doi.org/10.1371/journal.pone.0363328.g003 Kaplan-Meier survival curves for all-cause mortality in propensity-score matched cohorts. Each panel plots survival probability (%) against years after index surgery. Shaded bands denote the 95% confidence interval around each survival estimate. Hazard ratios were estimated from Cox proportional-hazards models fit within each follow-up window. (A) Adult craniopharyngioma vs. matched non-craniopharyngioma controls. Blue curves represent craniopharyngioma while red curves represent the matched control cohort. (B) Transsphenoidal vs. transcranial resection. In an analysis stratified by treating-center type, patients treated at non-academic centers had significantly higher long-term rates of composite endocrine complications (10-year: 30.7% vs. 41.8%; HR 0.71, 95% CI 0.53–0.94, p = 0.02) and epilepsy (15-year: 2.0% vs. 4.5%; HR 0.46, 95% CI 0.22–0.94, p = 0.03) than those treated at academic centers. Notably, most patients underwent surgery at academic centers (6,064 vs. 593) ( S1 File , Figure A3 and Tables A7–A10). Long-term outcomes by surgical approach in unmatched analysis Prior to PSM, outcomes were first examined in the full unmatched TSR (n = 2,558) and TCR (n = 1,452) populations. At 1 year, TSR was associated with higher rates of CSF leak (9.44% vs. 6.15%; HR:1.56, 95%CI:1.22–1.99, p < 0.001), and lower rates of hydrocephalus (0.84% vs. 2.64%; HR:0.31, 95%CI:0.18–0.54, p < 0.001), blindness (2.37% vs. 4.24%; HR:0.55, 95%CI:0.37–0.80, p = 0.002), and EVD placement (0.43% vs. 1.06%; HR:0.403, 95%CI:0.185–0.877, p = 0.02). These differences persisted at 10 years, with lower rates of shunt placement and DI also observed ( S1 File , Tables A15–A18). Long-term outcomes by surgical approach in matched analysis To account for baseline differences between surgical cohorts, a PSM analysis was performed yielding 1,199 matched pairs. At 1 year, TSR was associated with higher rates of CSF leak (10.66% vs. 6.58%; HR:1.65, 95%CI:1.25–2.19, p < 0.001), but lower rates of hydrocephalus (0.96% vs. 2.66%; HR:0.35, 95%CI:0.18–0.71, p = 0.002), blindness (2.52% vs. 4.54%; HR:0.54, 95%CI:0.33–0.86, p = 0.009), and radiation treatment (6.62% vs. 9.06%; HR:0.70, 95%CI:0.52–0.94, p = 0.02). No other measured visual, endocrine, vascular, neurologic, or treatment-related outcomes differed significantly at 1 year. At 10 years, TSR was associated with lower rates of hydrocephalus (2.19% vs. 3.73%; HR:0.57, 95%CI:0.35–0.93, p = 0.02), DI (8.88% vs. 12.47%; HR:0.69, 95%CI:0.52–0.91, p = 0.01), epilepsy (2.03% vs. 4.19%; HR:0.47, 95%CI:0.29–0.76, p = 0.003), and blindness (5.13% vs. 8.10%; HR:0.61, 95%CI:0.43–0.86, p = 0.01). In contrast, CSF leak remained more common in the TSR cohort (10.59% vs. 8.09%; HR:1.32, 95%CI:1.02–1.72, p = 0.04). TSR was also associated with higher rates of hypopituitarism (34.43% vs. 28.27%; HR:1.24, 95%CI:1.06–1.46, p = 0.01) and comp
## Related Clinical Research

- [Cardiometabolic multimorbidity among Ghanaian clinic patients: clinical, lifestyle and genetic cor](https://medichelpline.com/clinical-feed/plos-one-19-cardiometabolic-multimorbidity-and-associated-clinical-lifestyle-and-genetic.md)
- [Obesity-related multimorbidity patterns and reduced quality of life in Iranian adults](https://medichelpline.com/clinical-feed/bmj-open-19-obesity-related-patterns-of-multimorbidity-and-their-association-with-health.md)
- [Spatial Clustering of CKM Risk Burden Across US Census Tracts: Aging, Environment, and Socioeconom](https://medichelpline.com/clinical-feed/medrxiv-10-aging-structural-and-neighborhood-environmental-correlates-of-cardiovascular.md)
- [Cardiovascular risk and mortality after statin initiation: achieved LDL and non‑HDL levels in a 3‑](https://medichelpline.com/clinical-feed/plos-medicine-0-risk-of-cardiovascular-events-and-mortality-associated-with-ldl-and-non-hdl.md)
- [Medicinal Plants and Diabetic Nephropathy: Phytochemicals, Mechanisms, and Therapeutic Potential](https://medichelpline.com/clinical-feed/frontiers-in-immunology-2-medicinal-plants-in-diabetic-nephropathy-bioactive-compounds-mechanisms-and.md)

## Navigation
- [← Back to General Feed](https://medichelpline.com/clinical-feed/general.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.